EU/3/10/833

About

On 23 February 2011, orphan designation (EU/3/10/833) was granted by the European Commission to Biological Consulting Europe Ltd, United Kingdom, for doxorubicin hydrochloride (in heat-sensitive liposomes) for the treatment of hepatocellular carcinoma.

The sponsorship was transferred to FGK Representative Service GmbH, Germany, in January 2019.

Key facts

Active substance
Doxorubicin hydrochloride (in heat-sensitive liposomes)
Disease / condition
Treatment of hepatocellular carcinoma
Date of decision
23/02/2011
Outcome
Positive
Orphan decision number
EU/3/10/833

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Heimeranstrasse 35
80339 Munich
Germany
Tel:  + 49 89 893 119 28
E-mail: clinical.studies@fgk-rs.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating